niacinamide has been researched along with thalidomide in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (23.08) | 18.7374 |
| 1990's | 2 (5.13) | 18.2507 |
| 2000's | 11 (28.21) | 29.6817 |
| 2010's | 17 (43.59) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Kochhar, DM | 1 |
| Wolpert, L | 1 |
| Meynadier, J; Peyron, JL | 1 |
| Metcalf, WK | 1 |
| Gershbein, LL | 1 |
| Fratta, ID | 1 |
| Dietrich, A; Grätz, R; Klewer, M; Kröger, H; Miesel, R; Ockenfels, H | 1 |
| Dietrich, A; Kröger, H; Miesel, R; Ockenfels, H; Ohde, M; Rajnavölgyi, E | 1 |
| AARONSON, S; BAKER, H; FRANK, O; HUTNER, SH; LEEVY, CM; ZIFFER, H | 1 |
| BAKER, H; FRANK, O; HUTNER, SH; SOBOTKA, H | 1 |
| FELISATI, D | 1 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 2 |
| Curtiss, FR | 1 |
| Hussar, DA | 1 |
| Miller, K | 1 |
| Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI | 1 |
| Claflin, JE; Crean, S; Lahn, M; Linz, H; Noel, JK; Ranganathan, G | 1 |
| Daher, IN; Yeh, ET | 1 |
| Chan, P; Epstein, R; Poon, RT; Yau, T | 1 |
| Horn, L; Sandler, AB | 1 |
| Aragon-Ching, JB; Dahut, WL | 1 |
| Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Anderson, KC; Podar, K | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A | 1 |
| Aparo, S; Bakalarski, P; Berz, D; Charpentier, KP; Dubel, G; Eng, Y; Espat, J; Faricy-Anderson, K; Kaubisch, A; Luppe, D; Mantripragada, K; Martel, D; Miner, T; Perez, K; Plette, A; Rosati, K; Safran, H; Victor, J; Wingate, P | 1 |
| Bedikian, AY; Falchook, G; Fu, S; Ganesan, P; Hong, DS; Janku, F; Kies, M; Kurzrock, R; Laday, S; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Wolff, RA | 1 |
| Fan, L; Han, TT; Li, JY; Xu, W | 1 |
| Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL | 1 |
| Warren, RB; Yiu, ZZ | 1 |
| Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Abraham, LJ; Callus, BA; Diepeveen, LA; Dwyer, BJ; Elsegood, CL; Finch-Edmondson, ML; Kampmann, SS; Kong, GS; Olynyk, JK; Passman, AM; Stewart, SG; Tirnitz-Parker, JE; Woo, K; Yeoh, GC; Yeung, SY | 1 |
| Althouse, SK; Chiorean, EG; Clark, RS; Loehrer, PJ; Shahda, S; Spittler, AJ | 1 |
| Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ | 1 |
| Cardwell, LA; Cline, A; Feldman, SR | 1 |
18 review(s) available for niacinamide and thalidomide
| Article | Year |
|---|---|
Mechanisms of limb development and malformation.
Topics: Abnormalities, Drug-Induced; Animals; Cell Differentiation; Chick Embryo; Extremities; Genetics; Limb Deformities, Congenital; Morphogenesis; Niacinamide; Phenotype; Radiation Effects; Thalidomide | 1976 |
The pharmacological basis for the treatment of photodermatoses.
Topics: Antigens; Antimalarials; beta Carotene; Carotenoids; DNA; Female; Humans; Immunosuppression Therapy; Male; Niacinamide; Pellagra; Photosensitivity Disorders; Porphyrias; Porphyrins; PUVA Therapy; Skin Diseases; Sunlight; T-Lymphocytes; Thalidomide; Ultraviolet Rays; Uroporphyrinogen Decarboxylase; Uroporphyrins; Urticaria | 1986 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
Novel agents for the treatment of advanced kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2004 |
Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thalidomide | 2008 |
Vascular complications of selected cancer therapies.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cisplatin; Fluorouracil; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Thrombosis; Vascular Diseases | 2008 |
Evolution of systemic therapy of advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Somatostatin; Sorafenib; Thalidomide; Treatment Outcome | 2008 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
VEGF inhibitors and prostate cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Humans; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Quinazolines; Signal Transduction; Sorafenib; Thalidomide; Vascular Endothelial Growth Factors | 2009 |
Compounds in clinical Phase III and beyond.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2010 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles | 2016 |
Sorafenib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Proliferation; Humans; Lenalidomide; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thalidomide | 2016 |
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide | 2017 |
5 trial(s) available for niacinamide and thalidomide
| Article | Year |
|---|---|
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Lenalidomide; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Pain; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Immunologic Factors; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Sorafenib; Thalidomide; Young Adult | 2014 |
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide | 2016 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Outcome | 2017 |
16 other study(ies) available for niacinamide and thalidomide
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
The use of in vitro procedures in teratology.
Topics: Abnormalities, Drug-Induced; Aminopropionitrile; Aminopterin; Animals; Azaserine; Bromodeoxyuridine; Culture Media; Culture Techniques; Diazooxonorleucine; DNA; Dose-Response Relationship, Drug; Embryo, Mammalian; Embryo, Nonmammalian; Embryology; Extremities; Female; Gestational Age; Limb Deformities, Congenital; Niacinamide; Protein Biosynthesis; Teratogens; Thalidomide; Vitamin A; Vitelline Membrane | 1975 |
The relation of vitamin-B complex to the effect of thalidomide on the sensitivity of intracellular haemoglobin to oxidation.
Topics: Animals; Erythrocytes; Female; Glutethimide; Hemoglobins; Male; Niacinamide; Oxidation-Reduction; Phenobarbital; Pregnancy; Pyridoxine; Rats; Riboflavin; Thalidomide; Thiamine; Vitamin B Complex | 1967 |
Effect of transplanted tumor and various agents on liver regeneration during pregnancy.
Topics: Animals; Benzofurans; Carcinoma 256, Walker; Female; Fetal Death; Hepatectomy; Liver Regeneration; Naphthalenes; Neoplasm Transplantation; Niacinamide; Organ Size; Phenylbutazone; Pregnancy; Pregnancy, Animal; Pyrimidines; Rats; Thalidomide | 1966 |
Nicotinamide deficiency and thalidomide: potential teratogenic disturbances in Long-Evans rats.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Animal Feed; Animals; Birth Weight; Chlorpromazine; Congenital Abnormalities; Deficiency Diseases; Female; Fertility; Fetal Death; Fetal Diseases; Gestational Age; Liver; NAD; Niacinamide; Pregnancy; Pregnancy Complications; Rats; Rodent Diseases; Species Specificity; Thalidomide | 1969 |
Exacerbation of acetaminophen hepatotoxicity by thalidomide and protection by nicotinic acid amide.
Topics: Acetaminophen; Alanine Transaminase; Animals; Aspartate Aminotransferases; Drug Interactions; Liver; Male; Mice; Mice, Inbred Strains; Niacinamide; Thalidomide | 1995 |
Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice.
Topics: Animals; Arthritis; Arthritis, Rheumatoid; Cattle; Collagen; Disease Models, Animal; Drug Synergism; Enzyme Inhibitors; Humans; Immunization; Isoantibodies; Male; Mice; Mice, Inbred DBA; NADPH Oxidases; Neutrophils; Niacinamide; Poly(ADP-ribose) Polymerase Inhibitors; Respiratory Burst; Thalidomide; Tumor Necrosis Factor-alpha | 1996 |
Metabolic deficiencies in protozoa induced by thalidomide.
Topics: Animals; Euglena; Eukaryota; Humans; Invertebrates; Male; Niacinamide; Tetrahymena; Thalidomide | 1963 |
TOXICITY TO PROTOZOA OF THALIDOMIDE BREAKDOWN PRODUCTS; COUNTERACTION BY NICOTINIC ACID AND GLUTAMINE.
Topics: Animals; Eukaryota; Glutamine; Invertebrates; Metabolism; Niacin; Niacinamide; Nicotinic Acids; Pharmacology; Phthalic Acids; Research; Thalidomide | 1963 |
TERATOGENIC ACTION OF THALIDOMIDE.
Topics: Abnormalities, Drug-Induced; Female; Folic Acid; Glutamine; Niacinamide; Pregnancy; Pregnancy Complications; Pregnancy, Animal; Rabbits; Riboflavin; Teratogens; Thalidomide; Toxicology; Vitamin B Deficiency | 1964 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
New drugs 07, part I.
Topics: Abatacept; Acetanilides; Alprostadil; Anidulafungin; Antidiuretic Hormone Receptor Antagonists; Antifungal Agents; Antineoplastic Agents; Arabinonucleosides; Benzazepines; Benzenesulfonates; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Echinocandins; Fatty Acids; Humans; Hypoglycemic Agents; Immunoconjugates; Immunosuppressive Agents; Indoles; Insulin; Insulin Detemir; Insulin, Long-Acting; Intercellular Signaling Peptides and Proteins; Lenalidomide; Lubiprostone; Niacinamide; Patient Education as Topic; Peptides, Cyclic; Phenylurea Compounds; Piperazines; Pyridines; Pyrroles; Ranolazine; Sorafenib; Sunitinib; Thalidomide; United States | 2007 |
[Therapy sequence for renal cell carcinoma--new aspects!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Approval; Humans; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Thalidomide | 2007 |
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Eye Neoplasms; Humans; In Vitro Techniques; Lenalidomide; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Thalidomide; Xenograft Model Antitumor Assays | 2007 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Immunologic Factors; Interferon-gamma; Lenalidomide; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocyte Subsets; Thalidomide | 2014 |
Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Lenalidomide; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Stem Cells; Thalidomide | 2016 |